HiTech Health
London, United Kingdom
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
76.8
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
○ Press
✓ EMA GMP (4)
○ MHRA GMP
Quick Facts: HiTech Health
- Signal Score
- 76.8/100 (as of 2026-10-29)
- Quality Compliance
- 100.0/100 — Clean EMA record: 4 active GMP certificates (no deductions)
- Headquarters
- London, United Kingdom
- Modalities
- Cell Therapy
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About HiTech Health
Pure-play CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
100.0
Clean EMA record: 4 active GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP
Clean EMA record: 4 active GMP certificates (no deductions)
FDA InspectionsNo US records on file
EMA GMP Certificates4 on record
Clean EMA record: 4 active GMP certificates (no deductions)
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
53.0
1 manufacturing site: London, UK
Modalities: Cell Therapy
Capacity assessment: 53.0/100
Sites: London, UK
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: London, UK
Modalities: Cell Therapy
Capacity assessment: 53.0/100
HiTech Health EMA GMP Compliance 4 certificates
2026-04
2026-04
2023-05
2023-05
Compliant
Non-Compliant
| Certificate | Site | Country | Inspection Date | Status |
|---|---|---|---|---|
| CRN00H3ZN/M12614/00001 | Hitech Health Limited | Ireland | 2026-04-09 | COMPLIANT |
| CRN00H3ZN/IMP12686/00001 | Hitech Health Limited | Ireland | 2026-04-09 | COMPLIANT |
| 33517/M12614/00001 | Hitech Health Limited | Ireland | 2023-05-08 | COMPLIANT |
| 33517/IMP12686/00001 | Hitech Health Limited | Ireland | 2023-05-08 | COMPLIANT |
Source: EMA EudraGMDP · Retrieved Nov 21, 2026
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source:
public careers pages
· Checked Nov 20, 2026
Frequently Asked Questions About HiTech Health
Does HiTech Health hold EMA or MHRA GMP certificates?
CDMO Signal tracks 4 EMA GMP certificates for HiTech Health.
What is HiTech Health's CDMO Signal Score?
HiTech Health has a Signal Score of 77/100, based on quality, operations, financial stability, and capacity data.
Evaluating HiTech Health for a manufacturing program?
Use the free AI matchmaker to compare HiTech Health against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
eXmoor Pharma
Bristol, United Kingdom
Signal Score: 78.1
Cell Therapy, AAV
Symbiosis Pharmaceutical Services
Stirling, United Kingdom
Signal Score: 76.8
Cell Therapy
Rose BioSolutions
Rockville, MD · Memphis, TN · Keele, United Kingdom
Signal Score: 64.0
AAV, Lentiviral, Adenoviral, Plasmid, Cell Therapy, CAR-T
Ori Biotech
London, United Kingdom
Signal Score: 59.0
CAR-T, Cell Therapy
Cell and Gene Therapy Catapult
Stevenage, United Kingdom
Signal Score: 59.0
CAR-T, Cell Therapy, AAV
Compare HiTech Health with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.